Helix BioPharma（HBPC.F）株式概要ヘリックス・バイオファーマ・コーポレーションはカナダで免疫腫瘍学の会社として活動している。 詳細HBPC.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間6%増加しました。 リスク分析株式の流動性は非常に低い 収益が 100 万ドル未満 ( CA$0 )キャッシュランウェイが1年未満である 過去1年間で株主の希薄化は大幅に進んだ +1 さらなるリスクすべてのリスクチェックを見るHBPC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.71該当なし内在価値ディスカウントEst. Revenue$PastFuture-11m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesHelix BioPharma Corp. 競合他社ExagenSymbol: NasdaqGM:XGNMarket cap: US$90.1mAdicet BioSymbol: NasdaqCM:ACETMarket cap: US$76.1mPelthos TherapeuticsSymbol: NYSEAM:PTHSMarket cap: US$90.6mCitius OncologySymbol: NasdaqCM:CTORMarket cap: US$73.1m価格と性能株価の高値、安値、推移の概要Helix BioPharma過去の株価現在の株価CA$1.7152週高値CA$1.7352週安値CA$1.71ベータ-0.311ヶ月の変化-1.16%3ヶ月変化n/a1年変化185.00%3年間の変化135.86%5年間の変化-53.94%IPOからの変化-87.24%最新ニュースお知らせ • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.お知らせ • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.お知らせ • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.お知らせ • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.お知らせ • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.お知らせ • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.最新情報をもっと見るRecent updatesお知らせ • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.お知らせ • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.お知らせ • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.お知らせ • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.お知らせ • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.お知らせ • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.お知らせ • Dec 18Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025.お知らせ • Apr 09Helix BioPharma Corp. announced that it has received CAD 1.915 million in fundingOn April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder.お知らせ • Mar 30Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in fundingHelix BioPharma Corp announced private placement financing of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws.お知らせ • Feb 14+ 1 more updateHelix BioPharma Corp. Appoints Praveen Varshney as Chief Financial OfficerHelix BioPharma Corp. announced that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary. Mr. Praveen Varshney has been a principal of Varshney Capital Corp. since 1991. He's also a Founding Director of Pyfera Growth Capital &a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus. Mr. Varshney obtained his UBC Sauder B Comm in 1987 and is a FCPA, FCA. He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director &Charter Member of the Vancouver since 2000. He has been a Co-Founder, Director or Officer of many publicly traded and private companies over the years including Mogo Inc. and Little Kitchen Academy. He"s also on three charity boards such as The Vancouver Foundation and Foundations for Social Change.お知らせ • Nov 08Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024.お知らせ • Oct 13Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsHelix BioPharma Corp. announced that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023. During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens. Poster Presentation Details: Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma. Abstract Number: 35494. Poster Presentation Date and Time: October 13, 12:30 pm - 4:00 pm. Location: Level 2, Exhibit Hall D. Poster Session B, Poster Number: B125.お知らせ • Aug 24Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in fundingHelix BioPharma Corp. announced a private placement financing of 16,655,557 common shares at a price of CAD 0.18 per common share for proceeds of CAD 2,998,000 on August 22, 2023. The common shares issued pursuant are subject to a statutory hold period of four months. Helix BioPharma Corp. announces that it has closed the first tranche of private placement financing for gross proceeds of CAD 2,998,000.お知らせ • Aug 23Helix BioPharma Corp. Announces Executive ChangesHelix BioPharma Corp. announced appointment of Mr. Janusz Grabski to the board of directors of the Company with an immediate effect. Mr. Grabski is a lawyer specialized in corporate law and real estate law with over twenty years of experience. Mr. Grabski is based in Warsaw, Poland. Alongside the appointment, the Company also announced resignation of Mr. Christopher Maciejewski from the board of directors of the Company due to personal reasons.お知らせ • Nov 18Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023.株主還元HBPC.FUS BiotechsUS 市場7D-1.2%-3.0%-0.3%1Y185.0%32.9%26.7%株主還元を見る業界別リターン: HBPC.F過去 1 年間で32.9 % の収益を上げたUS Biotechs業界を上回りました。リターン対市場: HBPC.F過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。価格変動Is HBPC.F's price volatile compared to industry and market?HBPC.F volatilityHBPC.F Average Weekly Movementn/aBiotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: HBPC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のHBPC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20087Thomas Mehrlingwww.helixbiopharma.comHelix BioPharma Corp.はカナダで免疫腫瘍学の会社として活動している。同社の製品パイプラインは、固形癌の微小環境を中和する臨床段階の抗体-酵素コンジュゲート（AEC）であるL-DOS47、非小細胞肺癌の治療薬として第I相臨床試験中のLDOS001、非小細胞肺癌の治療薬として第I/II相臨床試験中のLDOS002、非小細胞肺癌の治療薬として第II相臨床試験中のLDOS003、膵臓癌の治療薬として第Ib/II相臨床試験中のLDOS006で構成されている。また、血管内皮増殖因子2受容体を標的とする抗体-DOS47結合体であるV-DOS47を開発している。モフィットがんセンターとは、L-DOS47の薬力学を研究し、L-DOS47と免疫チェックポイント阻害剤との併用の利点を決定するための共同研究契約を締結しており、テュービンゲン大学病院とは、CEACAM6を発現するがんモデルにおけるL-DOS47の治療反応を、前臨床代謝イメージングを用いて評価するための共同研究契約を締結している。ヘリックス・バイオファーマ社は2008年に設立され、カナダのバンクーバーに本社を置いています。もっと見るHelix BioPharma Corp. 基礎のまとめHelix BioPharma の収益と売上を時価総額と比較するとどうか。HBPC.F 基礎統計学時価総額US$90.59m収益（TTM）-US$3.05m売上高(TTM)n/a0.0xP/Sレシオ-29.7xPER（株価収益率HBPC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HBPC.F 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$4.20m収益-CA$4.20m直近の収益報告Jan 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.055グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率2.3%HBPC.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 13:50終値2026/05/18 00:00収益2026/01/31年間収益2025/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Helix BioPharma Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ahu DemirNOBLE Capital Markets, Inc.
お知らせ • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.
お知らせ • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.
お知らせ • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.
お知らせ • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.
お知らせ • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.
お知らせ • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.
お知らせ • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.
お知らせ • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.
お知らせ • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.
お知らせ • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.
お知らせ • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.
お知らせ • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.
お知らせ • Dec 18Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025.
お知らせ • Apr 09Helix BioPharma Corp. announced that it has received CAD 1.915 million in fundingOn April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder.
お知らせ • Mar 30Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in fundingHelix BioPharma Corp announced private placement financing of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws.
お知らせ • Feb 14+ 1 more updateHelix BioPharma Corp. Appoints Praveen Varshney as Chief Financial OfficerHelix BioPharma Corp. announced that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary. Mr. Praveen Varshney has been a principal of Varshney Capital Corp. since 1991. He's also a Founding Director of Pyfera Growth Capital &a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus. Mr. Varshney obtained his UBC Sauder B Comm in 1987 and is a FCPA, FCA. He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director &Charter Member of the Vancouver since 2000. He has been a Co-Founder, Director or Officer of many publicly traded and private companies over the years including Mogo Inc. and Little Kitchen Academy. He"s also on three charity boards such as The Vancouver Foundation and Foundations for Social Change.
お知らせ • Nov 08Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024.
お知らせ • Oct 13Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsHelix BioPharma Corp. announced that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023. During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens. Poster Presentation Details: Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma. Abstract Number: 35494. Poster Presentation Date and Time: October 13, 12:30 pm - 4:00 pm. Location: Level 2, Exhibit Hall D. Poster Session B, Poster Number: B125.
お知らせ • Aug 24Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in fundingHelix BioPharma Corp. announced a private placement financing of 16,655,557 common shares at a price of CAD 0.18 per common share for proceeds of CAD 2,998,000 on August 22, 2023. The common shares issued pursuant are subject to a statutory hold period of four months. Helix BioPharma Corp. announces that it has closed the first tranche of private placement financing for gross proceeds of CAD 2,998,000.
お知らせ • Aug 23Helix BioPharma Corp. Announces Executive ChangesHelix BioPharma Corp. announced appointment of Mr. Janusz Grabski to the board of directors of the Company with an immediate effect. Mr. Grabski is a lawyer specialized in corporate law and real estate law with over twenty years of experience. Mr. Grabski is based in Warsaw, Poland. Alongside the appointment, the Company also announced resignation of Mr. Christopher Maciejewski from the board of directors of the Company due to personal reasons.
お知らせ • Nov 18Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023.
